Precision BioSciences, Inc.

Join us today at 3 pm ET for Precision's Fireside Chat at the Guggenheim Inaugural Healthcare Conference. Webcast link: https://loom.ly/DrdDgfE *A live webcast of the presentation will also be accessible on Precision’s website in the Investors section under Events & Presentations at https://loom.ly/UwOZo7s #GeneEditing #Biotech #DTIL

We're one week away from our Hepatitis B Virtual Investor Event! Have you registered? ? Learn about PBGENE-HBV’s final preclinical safety data ? Gain insights into Phase 1 clinical trial plans ? Hear from leaders in the hepatitis field ? Connect with Precision's executive management team! To register, visit https://loom.ly/igX-DhU For more information, visit https://loom.ly/tM1fY88 #GeneEditing #Biotech #DTIL #HBV

Precision's Cassie Gorsuch, Ph.D., Head of Gene Therapy, and Alex Kelly, Chief Financial Officer, sat down with the Triangle Business Journal to discuss the recent clinical trial application (CTA) approval and plans for a Phase 1 clinical trial. Read the full piece at https://loom.ly/essjKbw To learn more about Precision's first CTA approval, visit https://loom.ly/5uS0qi0. #GeneEditing #Biotech #DTIL #HBV

Precision BioSciences Reports Third Quarter 2024 Financial Results & Provides Business Update! Listen as Alex Kelly, Chief Financial Officer, shares the highlights. For the full report, visit https://loom.ly/2crKARo #GeneEditing #Biotech #DTIL

Precision made it to the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress! Dr. Adam Mischler, PhD, Senior Scientist, Precision BioSciences Gene Discovery, presented a poster at ESGCT earlier this month, in Rome, Italy. The poster highlighted preclinical data demonstrating the ability of ARCUS to achieve high-efficiency gene insertion, gene replacement, and base correction via homology-directed repair (HDR). For more information, https://loom.ly/ZO4qnYk. #GeneEditing #Biotech #DTIL

Now that Precision Biosciences has received Clinical Trial Application approval for its PBGENE-HBV program, what's next? Join us virtually on Friday, November 15, at 7am PST / 10am EST, for a Hepatitis B Investor Event featuring key opinion leaders, members of Precision’s Hepatitis Scientific Advisory Board, and the executive management team for a discussion on the current unmet need, treatment landscape, a deeper dive into Precision’s PBGENE-HBV preclinical safety data, and Phase 1 clinical trial plans! For more information and registration, visit https://loom.ly/igX-DhU #GeneEditing #Biotech #DTIL #HBV

?? First Clinical Trial Application (CTA) Approval Received! Precision BioSciences received its first approval for a CTA to initiate a first-in-human study of PBGENE-HBV to treat chronic Hepatitis B. Precision remains laser-focused on execution, and our first CTA approval for PBGENE-HBV represents another significant milestone as we complete our transition to a clinical stage in vivo gene editing company. The Company has opened the Phase 1 clinical program and is moving towards dosing patients. For more information, visit https://loom.ly/5uS0qi0. #GeneEditing #Biotech #DTIL #HBV

Precision President & CEO, Michael Amoroso, will participate in the Longwood Boston CEO Conference's Expanding Platform Potential panel on Monday, October 28 at 11:10 AM ET. For more information, visit?https://loom.ly/DrdDgfE. #GeneEditing?#Biotech?#DTIL?#HBV

We're another step closer to a potentially curative therapy for Chronic Hepatitis B! Today, Precision BioSciences announced the submission of Clinical Trial Applications (CTA) to initiate a Phase 1 study evaluating PBGENE-HBV. PBGENE-HBV is the Company’s wholly-owned in vivo gene editing program designed to potentially cure chronic hepatitis B virus (HBV) by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes. These regulatory submissions are the culmination of our team’s dedication, commitment and highly productive interactions with global regulators as we develop the first clinical stage in vivo gene editing program for chronic hepatitis B virus, recognized as one of the largest global public health problems by the World Health Organization with an estimated 300 million people afflicted globally. For more information, read our latest press release, https://loom.ly/z_AysCM. #GeneEditing #Biotech #DTIL #HBV

We're another step closer to a potentially curative therapy for Chronic Hepatitis B! Today, Precision BioSciences announced the submission of Clinical Trial Applications (CTA) to initiate a Phase 1 study evaluating PBGENE-HBV. PBGENE-HBV is the Company’s wholly-owned in vivo gene editing program designed to potentially cure chronic hepatitis B virus (HBV) by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes. These regulatory submissions are the culmination of our team’s dedication, commitment and highly productive interactions with global regulators as we develop the first clinical stage in vivo gene editing program for chronic hepatitis B virus, recognized as one of the largest global public health problems by the World Health Organization with an estimated 300 million people afflicted globally. For more information, read our latest press release, https://loom.ly/z_AysCM. #GeneEditing #Biotech #DTIL #HBV